Within brain cancer cell lines in this cohort, high SNX10 expression was associated with resistance to a number of multitargeted RTK inhibitors, including pazopanib, tivozanib, and lenvatinib, which each target VEGFRs, PDGFRs, FGFRs, and KIT with varying selectivity (Figure 8, A and B). The gene discussed is SNX10; the disease is brain cancer.